DIAMEDICA

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company committed to changing the treatment paradigm for acute ischemic stroke (AIS) and cardio-renal disease. Our initial product candidate, DM199, mimics the behavior of naturally occurring human tissue kallikrein-1 (KLK1) proteins to increase collateral circulation in stroke-affected tissue and improve blood pressure control and overall kidney function... DiaMedica Therapeutics is a biopharmaceutical company that specializes in creating synthetic proteins to treat a variety of conditions... DiaMedica Therapeutics is developing DM199, a recombinant protein replacement therapy intended to restore normal, healthy levels of a protein known as human tissue kallikrein-1 (KLK1). KLK1 is a naturally-occurring protein believed to stimulate the production of nitric oxide and prostaglandin - critical local hormones that work synergistically to improve blood flow and reduce inflammation. We believe that DM199 has the potential to..

Also known as: DiaMedica Therapeutics, DiaMedica Therapeutics, Inc.

Primary location: Minneapolis United States